Try our Advanced Search for more refined results
Life Sciences - October, 2019
356 articles
- Opioid MDL Attys Poised To Debate Next Bellwether Trials
- Boston Scientific Says Sanctions Stem From 'Fictional Story'
- Ill. Silicone Maker To Probe Possible Contamination After Fire
- Michigan Vape Co. Drops Federal Suit After Ban Paused
- Vanda Pharma Wants Del. Derivative Suit Moved To NY
- IP Law Group Urges High Court To Fix Patent Eligibility
- Fed. Circ. Rules PTAB Judge Appointments Unconstitutional
- 5 Trends Influencing RFPs For Law Firms
- Fed. Circ. Told PTAB Standards 'Eviscerate' Patent Rights
- Biopharma Investor's Letter Dooms Officer Salary Suit
- 2nd Circ. Halves $19.4M Forfeiture In Valeant Kickback Case
- 2 Biotechs Raise Combined $116M After IPOs Price Low
- Pa. Justices To Say If Probationers Can Use Medical Marijuana
- Biotherapeutics Co. Raises $75M In Series B Financing Round
- Arizona's Purdue Suit Violates Ch. 11 Law, High Court Told
- Mass. Judge Refuses To Halt Tweaked Statewide Vape Ban
- Health Care Ad Agency Settles DOJ Fraud Claims For $70M
- Zetia Generic Delay Was A Conspiracy, Court Told
- Sens. Urge Changes At USPTO To Improve Patent Quality
- Fed. Circ. Won't Restore Merck's $2.5B Patent Win Over Gilead
- Tax Court Decision May Open Up New Challenges To 280E
- Dispute Over CBD Sale Doesn't Belong In Colo., Vendor Says
- McKesson Can't Ditch Generic Drug Price-Fixing Fraud Suit
- Vivo Capital Collects $1.43B For Health Care Investment Fund
- 2nd Circ. Mulls Legality Of MD's 'Icky' Drug Stock Trades
- MDLs Are Redefining The US Legal Landscape
- Calif. Labor Law For Cannabis Cos. May Be Unconstitutional
- L'Oreal Seeks DQ Of Lerner David In Cosmetics IP Row
- What Industry, Investors Think Of The Proposed CFIUS Regs
- Invisalign Maker Exits Shareholder Suit Over Expiring Patents
- Judge Rips Risperdal Trial Team's 'Fabricated' Recusal Bid
- 2nd Circ. Upholds Ex-Katten Atty's Shkreli Fraud Conviction
- Missouri Medical Marijuana Group Asks State For Vaping Regs
- Allergan's $750M Deal Among Pharma's Top Antitrust Payouts
- Mitsui Can't Trim Claims It Stole Irrigation System Technology
- New Mass. Vape Ban 'A Mockery' Of Court Orders, Shops Say
- Mallinckrodt Defends Price Hike As Necessary To Save Drug
- Retailers Fight To Keep 3-Way Zetia Conspiracy Claim In MDL
- On-Sale Bar Ruling Invites 'Exploitation,' Justices Told
- Fed. Circ. Tells PTAB To Review All Claims Of Drug Test Patent
- Why I Became A Lawyer: Being There For Families In Trouble
- Grunenthal Earns PTAB Win In Challenge To Pain Treatment IP
- Protecting Against Corruption In State Cannabis Licensing
- Labaton, Levi & Korsinsky Seek $4.7M Fees For Prothena Suit
- Hemp Regulation Turns Corner With New USDA Rule
- Drugmakers Ink $242M Settlement In Ill. Medicaid Fraud Case
- J&J Discloses Grand Jury Subpoena For Opioid Distributions
- Utah Judge Puts Emergency Flavored Vape Rule On Hold
- Calif. Cannabis Patient Takes Edible Eviction Case To 9th Circ.
- Foley Hoag Partner Takes Over As AIPLA President
- FTC Rips Gilead's 'Erroneous' Argument In HIV Drug Rumble
- Insys Doc's Sentence Called A Warning To Medical Community
- 3rd Circ. Revives Merck's Arbitration Bid In Vaccine Suit
- Takeda Hid 'Dangerously Defective' Gout Drug's Risks
- Philly Jury Hits Vein Filter Co. With $34M Defect Award
- Best Practices For US-Canada Virtual Mass Tort Teams
- Chinese Distributor Can't Pause US Co.'s Trade Secrets Suit
- Confronting Plaintiffs Attorney Advertising Abuses
- Allergan Paying $750M To End Namenda Antitrust Fight
- PixarBio CEO Found Guilty In Stock Fraud Case
- 5 Firms Guide Fintech, Biotech IPOs Totaling $295.8M
- Romanucci Atty Will Lead Sterigenics Emissions Suits In Ill.
- CBD Rules In Limbo As FDA Grapples With New Cannabis Era
- Woman Wants New Trial In Sanofi Chemo Drug Bellwether
- Silicone Maker Owes $1.6M After Deadly Blast, OSHA Says
- Vein Filter Patient Could Die, Philly Jury Told At Trial's End
- In Lung Injuries Probe, Officials Are Looking Beyond THC
- Glancy Prongay & Murray Will Lead Omnicell Stock Drop Suit
- PE Firm's Bid To Force Sale of Colo. Cannabis Retailer Tossed
- Pharmacy Claims Online Rx Co. Strangled Market
- Novartis Sues Indian Generic Cos. Over Heart Failure Drug IP
- Reckitt Spared Fees In 'Close Call' After Losing Mucinex Suit
- Ethicon Can't Escape Damages Claims In Pelvic Mesh Suit
- $16.7M AbbVie Inversion Settlement Gets Final Approval
- Lilly Says It Didn't Give Up Alternatives By Narrowing Patent
- Fed. Circ. Rehearing Requests Patent Attys Should Watch
- Counseling Cannabis Cos. Requires A Holistic Approach
- States Are Wrong To Block Local Gov'ts From Opioid Suits
- Patient Assistance Groups Settle Kickback Claims For $6M
- Cooley-Led Fertility Benefits Co.'s $130M IPO Misses Target
- Goodwin-Led Cabaletta Prices Below Range With $75M IPO
- Recent Antitrust Lessons For The Life Sciences Industry
- CVS Yanks J&J Baby Powder From Stores After Recall
- RI Flavored Vape Ban Latest To Face Court Challenge
- Associates Found Guilty In Doc's Major Oxy-Pushing Scheme
- Canadian Boutique Woods Adds Squire Patton Int'l Arb. Atty
- Pfizer's PTAB Appeal 'At War With Itself,' Fed. Circ. Told
- FDA Yanks Homeopathy Compliance Policy As Inadequate
- Chancery Orders Keryx To Turn Over Akebia Merger Records
- 4th Circ. Wrong To Dismiss Pelvic Mesh Appeal, Firm Says
- DOJ Strikes $6.4M Deal With Engineering Co. Over Billing Spat
- Deals Rumor Mill: Paysafe, Reynolds, Banijay Group
- Vape Co. Must Pull Illegal Ads For 100 Products, FDA Warns
- GSK Loses Bid To End 53 Zofran Birth Defects Cases
- UK Outlines Issues With Illumina's $1B DNA Sequencing Buy
- Examine Diversity Jurisdiction By Drilling Into Citizenship
- Device Maker, Execs To Pay $6M To End Feds' FCA Claims
- Loestrin Buyers' $1M Lupin Deal Gets Initial Approval
- New Technology Could Shape How Patents Are Valued
- Hong Kong Childhood Can't Diminish J&J Talc Risk, Jury Told
- 4 Takeaways From The USPTO's Patent Eligibility Update
- No Class Cert. In Boston Scientific Robocall Suit, Judge Says
- Okla. Judge Temporarily Blocks Reversible Abortion Info Law
- Birth Defect Report Trimmed By Judge In Zofran MDL
- IRS Bar On Pot Biz Deductions Constitutional, Tax Court Says
- Fla. Pharma Lab Says Patent Licensee Hid Payments
- Surgeon General Warns Senate About Perils Of Legalizing Pot
- American With Greek Ties Denied Bail In Insider Trading Case
- Ky. AG Announces $40M In Settlements With Bayer, Reckitt
- Where Law Firm Partners Go When Changing Jobs
- FDA Struggles To Foster An Affordable Biosimilar Insulin
- Nerve Repair Co. Says Derivative Suit Lacks Demand Futility
- FDA To Require Warning Labels On Breast Implants
- Asbestos Slipped Into J&J's Talc Supply, LA Jury Hears
- Feds Slam Pharma CEO's Bid To Nix Opioid Trafficking Charge
- Takeda Unit's Workers Get OK On $4.8M Deal In Wage Suit
- PTAB Allows Amendments To Jevtana Patent On Remand
- Momenta, Sandoz Can't Pause Blood-Clot Drug Antitrust Suit
- 10x Genomics To Pay Becton $25M In Cell Analysis IP Deal
- 'Mootness Fees' Are Beyond Court's Purview, 7th Circ. Hears
- California's Pot Regulation Maze Keeps Businesses On Edge
- Goldman Banker Denies Insider Trading As Gov't Suspects 6
- 3 Ways To Leverage Vulnerability For Lawyer Well-Being
- Hyland's Must Face Revived Suit Over Infant's Death
- Clinical Trials And Specific Jurisdiction After Bristol-Myers
- FDA, FTC Issue Warning On Claims CBD Can Treat Diseases
- The FDA Regulatory Landscape For Tobacco And Cannabis
- Cooley-Led Rapt Therapeutics Renews IPO Plans
- RI Governor Sues Lawmakers Over Control Of Cannabis Regs
- Pfizer, Sanofi Sued Over Possible Zantac-Cancer Link
- Pot Co. Harborside Gets $11M Bill After Tax Code Fight
- 3rd Circ. Declines To Reconsider J&J Remicade Antitrust Case
- Pharma Co. Blames BakerHostetler For Investor Row
- $48B Opioid Deal Outcry May Presage Plaintiff Infighting
- Lead Counsel Field In Curaleaf Stock Suit Narrowed To 2
- Oregon Pot Shop Will Give Up License Over Same-Day Sales
- Fed. Circ. Backs PTAB Ruling On Corning Cell Culture IP Row
- State AGs Reach $48B Proposed Deal To End Opioid Cases
- Keeping Sponsored Content On The FTC's Good Side
- Workers Say J&J Could Have 'Told Truth' On Talcum Powder
- Medical Pot Co. Worker Sues For Retaliation, Discrimination
- 2nd Circ. Revives Part Of EmblemHealth Execs' Benefits Suit
- Novartis Hit With Retaliation Suit Over Kickback Scheme
- Cooley, Baker McKenzie Steer Vaccine Deal Worth Up To $1.06B
- Kirkland Leads Danaher In $750M Divestiture For GE Deal
- High Court Passes On Lilly's $20M Cialis Patent Loss
- Opioid Trial Halted By Drug Cos.' 11th Hour $260M Deal
- Humana Slaps Generic-Drug Makers With New Price-Fix Suit
- McKesson Faces Uphill Fight To Toss Investor Price-Fix Suit
- Fight Over Utah's Medical Pot Effort Bumped To State Court
- DC Circ. Tosses Medical Pot Researcher's Fight With DEA
- La. Insurer Sues Pharma Cos. Over Opioid Crisis
- Dova Pharma Hit With Investor Suit Over $915M Sobi Tie-Up
- PTAB Gives Sanofi First-Ever Early Feedback On Amendments
- AstraZeneca's IP Suit Sent To W.Va. On TC Heartland Grounds
- Ill. City Ran To Court In Discovery Row, Express Scripts Says
- New Data Shows BigLaw's True Profitability
- PTAB Told To Weigh Invalid Claim Language In Ethicon Patent
- Health Hires: White & Case, Epstein Becker
- How 280E Became The Pot Industry's Boogeyman
- NECC Pharmacists Lose Bid For New Trial In Meningitis Case
- Zoning Compliance Tips For NJ Medical Marijuana Facilities
- J&J Pans Judge's 'Partisan Glee' After $8B Risperdal Verdict
- J&J Recalls Asbestos-Tainted Baby Powder Flagged By FDA
- Ex-Biotech Exec Agrees To Penalty For Deceiving Auditors
- What To Watch As Opioid MDL Nears Moment Of Truth
- Judge Questions Eagle's Orphan Drug Market Exclusivity
- Vein Filter Co. Boss Dinged For Talking To Plaintiff From Stand
- New USPTO Patent Eligibility Guidance Aims For More Clarity
- Oregon's Flavored Vape Ban Put On Hold Amid Legal Fights
- Ex-Okla. Gov't Atty Admits Fake Death Threats Over Pot Laws
- Under Siege, Juul Pulls Most Flavors From US Market
- Actavis Asks Full Fed. Circ. To Nix 'Amorphous' Panel Ruling
- Cooley, Linklaters Steer $69M Biotech IPO, Private Placement
- Insys Exec Trial Fair Despite Alleged Weil Conflict, Judge Says
- Boston Scientific Sanctioned For 'Shenanigans' In FCA Suit
- Mylan Case Shows SEC Stance On Disclosing Investigations
- AmerisourceBergen Brass Sued In Del. Over Drug Scheme
- SmileDirect Accuses Calif. Dental Board Of Harassment
- HHS Anti-Kickback Proposal Features 3 Key Safe Harbors
- J&J To Pay States $117M To Quell Pelvic Mesh Suits
- 8 Best Practices For Cannabis Transaction Due Diligence
- Pa. Justices Ask If Judge Delved Too Deep Into Science
- Vape Flavor Ban May Create Black Market, Lawmakers Told
- Toss 3-Way Zetia Conspiracy Claim, Judge Says
- Mass. Vaping Illnesses Mount As Legal Fight Over Ban Swirls
- Drug Cos. Float Deals Worth $50B To End Opioid Cases
- Shkreli Asks Justices To School 2nd Circ. On Securities Fraud
- Allergan Clashes With Buyers Over Cert. Bid In Antitrust MDL
- PTAB Won't Rehear Challenge To Prostate Cancer Drug Patent
- Insys Judge Unsure If Execs' Bribes Equal Drug Dealing
- Sandoz Revealed Trade Secrets In Antitrust Suit, Court Told
- Fla. High Court To Review Ruling Against Medical Pot Regs
- Suzanne Somers Says QVC Sabotaged Her Supplement Biz
- Goodwin-Led Cabaletta Bio Launches $87M IPO
- Alexion Set To Buy Clinical-Stage Pharma Biz In $930M Deal
- PTAB Sheds Light On Its Discretion To Hear IPRs
- Calif. Pot Cos. Must Sign 'Labor Peace' Deals After 20th Hire
- True Health Set To Begin Soliciting Votes On Ch. 11 Plan
- Missouri Appeals Court Erases $110M Talc Loss For J&J
- AmerisourceBergen Fights To Shield Opioid Docs At Chancery
- Michigan Vape Ban Halted After Claims Of Business Harm
- Fenwick Hires 2 Corporate Tech Pros On The West Coast
- High Court Declines To Hear 2 Patent Cases
- AbbVie Says Humira's Many Patents Is No Antitrust Violation
- 'Novel' Disclosure Issue Not Ready For Del. Supreme Court
- How AI Is Shaping FDA Medical Device Regulation
- Benefits, Biopharma And Boat Cos. Prep IPOs Totaling $360M
- Ex-Katten Atty's Jury Gripe Falls Flat With 2nd Circ. Judge
- IPRs Will Bleed Budgets And Innovation, States Warn Justices
- Grading The Presidential Candidates On Cannabis Policy
- High Court Won't Hear $2.7M Fees Appeal In BioScrip Deal
- Courts Keep Rejecting Litigation Funding Discovery Campaign
- Teva, Mylan, Other Generic Makers Hit With Price-Fixing Suit
- Fed. Circ. Backs PTAB's Gutting Of Duke Muscle Treatment IP
- Purdue Opioid Suits Get One-Month Pause, For Now
- Akin Gump's Local Focus Helped Land Bull Semen IP Win
- Generics, Others Back Impax Against FTC In 5th Circ.
- Sorin Settlement Offers Heart Patients Free Monitoring
- J&J Wins Second Asbestos-In-Talc Trial In A Week
- Mass. Gov. Fights To Keep Vape Ban Fight In Fed. Court
- Justices Seem Skeptical Of USPTO's Attorney Fee Arguments
- Restasis Payors Defend Class Cert. Bid In Allergan Suit
- How Emotionally Intelligent AI Could Assist With E-Discovery
- 8th Circ. Won't Rehear Monsanto Label Settlement Objection
- Chicago's Ex-Chief Judge Turns To 'Unfinished Business'
- FDA Focus: What BakerHostetler's Practice Chair Is Watching
- Glaukos Beats Last Of Rival's PTAB Challenges To Stent IP
- Job Wrongly Rescinded Over Medical Marijuana, Pa. Man Says
- Biotech, Bank Raise Combined $276M In Low-Priced IPOs
- 19 Abilify Claims Tossed As Lacking Proof In MDL Settlement
- Fed. Circ. Bars Generic Of Horizon Arthritis Drug Until 2027
- FCA Decision Tracker: Continued Interpretations Of Escobar
- Dental Startup Settles With Last Distributor In Boycott Suit
- Court Told Settlement Is The Best Result For Purdue Ch. 11
- Target Can't Pass Buck On Antibiotic Labeling Suit Costs
- Purdue Docs Show DOJ Deal Is Key To Ch. 11 Settlement
- J&J Nears OK For $6.3M Deal In Infant Tylenol False Ad Suit
- UBiome's Ch. 7 Case Conversion Approved In Del.
- Mich. Pot Testing Lab Fined $100K Over Flawed Methods
- 4 Firms Steer BioNTech's Downsized $150M IPO
- J&J Beats Class Action Over Opioid Health Insurance Costs
- The Number Of Cannabis-Centric Patents Is Getting High
- Ginkgo Bioworks Unveils $350M Biotech Spinoff Fund
- Preventable Risks Your Law Firm May Be Overlooking
- Ohio Trial In Opioid MDL Will Go Forward, 6th Circ. Says
- Covington & Burling, Latham Lead UCB's $2B Ra Pharma Buy
- Genetic Testing Co., 3 Others To Pay $42.6M Over FCA Claims
- Manatt Nabs Former McDermott Litigation Pro In LA
- Conn. Fits Teva Stock-Drop Suit Better Than Pa., Judge Says
- Chinese Distributor Can't Shake Trade Secrets Suit
- J&J Cleared By Calif. Jury In Talc Cancer Retrial
- $8B Philly Risperdal Verdict Ripe For Reduction, Experts Say
- Salix Pharma Beats Ex-Worker's FCA Retaliation Suit
- Fresenius To Pay $5M To Resolve Mass. Medicare Fraud
- Doc Who Led Major Oxy-Pushing Scheme Working With Feds
- 6 Ethics Tips For Attorneys Making Lateral Transfers
- Dickinson Wright Adds Cannabis Pro In Ohio
- FTC Warning On Plaintiffs Bar Advertising Is Timely
- Failure To Launch: The Patent Thicket Delay Of US Biosimilars
- Arizona Backs Out Of Purdue's Opioid Settlement
- PixarBio CEO's Greed Drove Stock Fraud, Boston Jury Hears
- Ex-Biomet Employee Can't Sue Over FCPA Firing: 7th Circ.
- Questions Swirl Around Opioid MDL Bellwether Trial
- Purdue's Sackler Family Loses Bid To Toss Mass. Opioid Suit
- Purdue Agrees To Put Off Consideration Of Ch. 11 Bonuses
- Levi & Korsinsky Picked To Lead Corcept Stock Drop Suit
- Ga. Jury Deadlocks In Latest J&J Talc Cancer Trial
- Sun Pharma Biosimilar Infringes Galderma Oracea Patents
- Takeda Avoids Most Claims In Actos Buyers' Antitrust Suit
- Full Fed. Circ. Asked To Undo Ruling That 'Disrespects' States
- Investor Suing Insys 'Not Listening' To Court, Judge Scolds
- Vein Filter Co. Ignored Potential Defects, Philly Jury Told
- NY's Most Prolific Oxy Doc Set To Plead Guilty, Feds Say
- J&J Slammed With $8B Verdict In Philly Risperdal Case
- Attys Denied Fee Set-Aside In Generics Antitrust Case
- Insys Seeks Extension Of Ch. 11 Plan Exclusivity Period
- Cannabis Cos. MedMen And PharmaCann Cancel $682M Deal
- Calif. Becomes 1st State To Target 'Pay-For-Delay' Drug Deals
- Merck Fires Back At Pfizer's Bid To Nix Trade Secret Suit
- J&J Talc Trial Closes With Each Side Blasting Other's Experts
- Hemp Co. Says Retailer Backed Out On CVS Distribution Deal
- USPTO To Revise Patent Term Rules After Fed. Circ. Ruling
- Philly Trial May Signal Future Vein Filter Claim Success
- Medical Co. Beats Claims Kid's Health Costs Got Dad Fired
- Fed. Circ. Reverses Brainlab MRI Patent Win
- Pomerantz, Wolf Haldenstein Vie To Lead Curaleaf Stock Suit
- Chinese Home Rental Biz Q&K Taps Cleary Gottlieb For IPO
- Justices Won't Hear Pharma Case Over FCA's Public Info Bar
- Monsanto's Final Roundup Trial Of 2019 Called Off Indefinitely
- J&J Can't Split Up Punitive Damages Trial In NJ Talc Case
- Employers Look To NJ High Court For Clarity On Medical Pot
- Nutrition Food Biz Joins Pipeline With Potential $525M IPO
- Bid To Boot Opioid Judge Raises Questions On Judicial Roles
- High Court Skips Ex-Pfizer Exec's ERISA Venue Case
- FTC Distorted Actavis Ruling In Generics Dispute, Impax Says
- Retailers Win Fight Over How To Carve Loestrin Antitrust Trial
- 25 AGs Say Purdue, Sackler Suits Should Proceed In Ch. 11
- Cooley Says Theranos Founder Holmes Not Paying Legal Bills
- FDA Chief Warns Against Use Of THC Vapes Amid Crisis
- Lab Investor Hits CBD Co. With Securities Fraud Suit
- Fed. Circ. Reverses Apotex's PTAB Win On OSI Cancer Drug
- Fed. Circ. Won't Revive 23AndMe Patent Axed Under Mayo
- AdvoCare Deal Puts FTC's 13(b) Authority In Spotlight
- 3 Things To Watch As USPTO's Fee Rule Hits The High Court
- Feds, States Won't Join Allergan Glaucoma Drug FCA Suit
- 7 Firms To Guide 3 IPOs Totaling $550M, Led By Biotech Cos.
- Unilever Deodorant Causes Stains It Claims To Stop, Suit Says
- USPTO's Battle For Attorney Fees, Explained
- NY, Calif., 24 Other States Fight Purdue's $38M Bonus Plan
- Ex-Rep. Chris Collins' Son Cops To Insider Trading Scheme
- NY Appeals Court Temporarily Blocks Flavored Vape Ban
- Risperdal Marketing Blocks Weren't For Kids, Pa. Jury Told
- CDC, FDA Ramp Up Vape Alarms As Lung Injury Cases Top 1K
- Clark Hill Says It Can't Be Sued Over Client's Settlement
- Icosavax Closes $51M Series A, Officially Launches
- Momenta, Sandoz Try To Pause Blood-Clot Drug Antitrust Suit
- DuPont Lined Its Pockets With Forfeited Benefits, Retiree Says
- Wilson Sonsini Steers Tenaya Therapeutics To $92M Series B
- FTC Seeks E-Cigarette Cos.' Data On Advertising, Sales
- 4 Plead Not Guilty To $99M Health Care Fraud In NJ
- Biotech Cancels IPO While 3 Others Launch In Choppy Market
- Vaping Crisis Raises New Liability And Insurance Issues
- Consider The Power Of Tactical Empathy
- Trevena Says Investors' Key Doc Contradicts Fraud Claims
- Ex-Theranos CEO Says Feds' Discovery Delay Is 'Deja Vu'
- Justices Urged To Heed 'Clarion Call' And Fix Patent Eligibility
- Medtronic Tells Justices $23M IP Verdict Flouts On-Sale Bar
- 4 Key Moments From J&J's Mesh Marketing Battle With Calif.
- AdvoCare Pays $150M To Settle FTC Pyramid Scheme Claims
- FDA Warns Of Security Flaws Lurking Within Medical Devices
- Gov't Says No Need To Revisit FCA Dismissal Authority
- 3rd Circ. Doubts Merck's Arbitration Bid In Vaccine Suit
- Opioid Distributor CEO Seeks To Toss Drug Trafficking Charge
- JPML Sends Juul Marketing Suits To Calif.
- Par Settlement Gets OK In Zetia Generic Delay Case
- FDA's New Medical Device Rules Speed Up Review Process
- The Problem — And Opportunity — Of Implicit Bias In The Bar
- White & Case, O'Melveny Lead $520M Progenics Buy
- Wisconsin Trailing In Midwest's Race To Legalize Cannabis
- UBiome Seeks Liquidation As Creditors Balk On DIP Loan
- J&J Inks $20.4M Deal Just Ahead Of Opioid Bellwether
- Undeveloped Patent Cases Leave Fed. Circ. In Dark: Judge
- Opioid MDL Judge Rips Ohio AG's Late Bellwether Attack
- Zydus Pins Its Patent Loss On Co-Defendant At Fed. Circ.
- Chancery OKs Anixa Reform Deal To End Repriced-Stock Suit
- Walgreens Ditches FCA Suit Over Prescription Autorefills
- Cannabis Industry Lobby Says FDA Should Regulate Legal Pot
- Sandoz Hit With Patent Suit Over Bausch's IBS Drug Xifaxan
- 2 Firms Eclipse Peers In IPO Work During Choppy September
- Judging A Book: Thapar Reviews Gorsuch's 'A Republic'
- Defendants' Chances On Daubert May Vary By Circuit
- DEA Slow To Act In Opioid Crisis, Inspector General Says
- Ex-NY Rep. Collins Cops To Insider Trading, Lying To FBI
- 2 Trends In DOJ Health Care Enforcement
- Drug Cos. Push 6th Circ. To Disqualify Opioid MDL Judge